drugset / Trial / NCT02294591

NACOS - The Effect of N-acetylcystein for Depressive Symptoms in Patients Suffering From Bipolar Depression

NCT02294591

Phase 2 Completed 80 enrolled Region Syddanmark
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial investigate add-on treatment with 3 g NAC vs. placebo in 20 weeks in patients suffering from bipolar depression. The primary outcome is MADRS-score, and the secondary outcomes are other psychometric evaluations oxidative stress biomarkers in urine.

Timeline

Start
2014-11
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator N-acetylcysteine Small molecule 3 g

Indications